For Patients

Clinical Trials for Unmet Needs

With an eternal focus on oncology, we are committed to advancing our pipeline and bringing patients a new wave of therapies. Our product pipeline is focused on novel targets that are uniquely expressed within cancer cells, enabling therapies that are highly targeted with potential to treat both rare and common cancers. With our pipeline of two clinical-stage compounds, we are supporting and/or planning several clinical studies to help address patient needs:

Cirmtuzumab

UC-961 (cirmtuzumab) in relapsed or refractory chronic lymphocytic leukemia

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

TK216

TK216 in Patients with Relapsed or Refractory Ewing Sarcoma